Cytochrome c release is a central step in the apoptosis induced by many death stimuli. Bcl-2 plays a critical role in controlling this step. In this study, we investigated the upstream mechanism of cytochrome c release induced by ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1), a recently discovered small molecule inhibitor of Bcl-2. 
Bcl-2 is overexpressed in many types of tumors, especially relapsed or chemoresistant malignancies (1) (2) (3) (4) (5) . It is an important target for anticancer drug development because Bcl-2 plays an essential antiapoptotic role against cell death induced by chemotherapeutic agents, radiation, growth factor withdrawal, or hypoxia (6) . By interrupting the function of Bcl-2, agents such as peptidic and organic molecules discovered recently have been shown to induce a potent direct and selective killing effect on target cells (7) (8) (9) . Like most apoptotic stimuli, these peptidic and organic inhibitors of Bcl-2 induce cytochrome c release, caspase-9/-3 activation, and DNA fragmentation. However, the precise molecular mechanism for cytochrome c release triggered by Bcl-2-targeting agents remains obscure.
Cytochrome c release is a central step in the initiation of caspase-dependent apoptosis (10 -12) . It has been demonstrated that overexpression of either mitochondria-or endoplasmic reticulum (ER) 1 -specific Bcl-2 prevents the induction of apoptosis by inhibiting the mitochondrial release of cytochrome c (13, 14) . Although the molecular mechanism governing the cytochrome c release regulated by Bcl-2 has yet to be fully characterized, what does appear to be important is the heterodimerization of Bcl-2 with proapoptotic proteins. Such heterodimerization directly or indirectly inhibits the apoptotic function, especially the homo-oligomerization of multidomain proapoptotic Bax or Bak that corresponds with the release of cytochrome c (15) (16) (17) (18) . Heterodimerization of Bcl-2 with proapoptotic proteins or BH3 domain-derived peptides from proapoptotic members such as Bax, Bak, or Bad has been demonstrated by NMR, cell-free protein-protein binding, and yeast two-hybrid studies (19 -21) . The anti-cytochrome c releasing effect of Bcl-2 can be suppressed by the overexpression of proapoptotic proteins such as Bax (22) . Conversely the cytochrome c releasing activity of proapoptotic proteins can be limited by the overexpression of Bcl-2 (16) . The ratio rather than the amount of antiapoptotic versus proapoptotic proteins determines whether apoptotic signaling can proceed (15, 17, 23) . Normally Bax exists as a soluble monomer in cytosol or is loosely associated with mitochondria. However, upon apoptotic stimulation, Bax translocates to mitochondria where it forms oligomers that are inserted into the outer mitochondrial membrane (24, 25) . The signals that trigger the translocation of Bax to mitochondria remain largely unknown. In synthetic membranes, Bcl-2 has been shown to directly inhibit the channel or pore forming activity of Bax (16) , which is consistent with the ability of Bcl-2 in preventing Bax oligomerization in outer mitochondrial membranes (22, 26) .
The antiapoptotic function of Bcl-2 is thought to be primarily derived from Bcl-2 presented in the mitochondria (10, 27) . 1 The abbreviations used are: ER, endoplasmic reticulum; HA14-1, ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; PTP, potential transient pore; ROS, reactive oxygen species; PARP, poly(ADP-ribose) polymerase; JC-1, 5,5Ј,6,6Ј-tetrachloro-1,1Ј,3,3Ј-tetraethylbenzimidazolcarbocyanine iodide; CCCP, carbonyl cyanide 3-chlorophenylhydrazone; ⌬⌿ m , change in mitochondrial membrane potential; BH3, Bcl-2 homology 3; H 2 DCFDA, succinimidyl ester of dichlorodihydrofluorescein diacetate; MEF, mouse embryonic fibroblast; MTS-tetrazolium, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Z-VAD-fmk, carbobenzoxyl-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone; carbobenzoxylvalyl-alanyl-Z, benzyloxycarbonyl; fmk, fluoromethyl ketone; GFP, green fluorescent protein; IAP, inhibitor of apoptosis.
However, growing evidence has indicated that Bcl-2 expressed on ER plays an important role in the inhibition of cytochrome c release and apoptosis (28) . An exclusive ER-targeted form of Bcl-2, Bcl-2/cb5 has been shown to prevent apoptosis in many types of cells induced by c-Myc, tunicamycin, brefeldin A, radiation, or Bax overexpression (13, 14, 29 -31) . The protective effect of Bcl-2/cb5 in cells suggests the presence of cross-talk between ER and mitochondria. However, the mediators that connect ER Bcl-2 and mitochondrial cytochrome c release remain to be identified. What does appear to be important is intracellular Ca 2ϩ signaling (32, 33) . It has been shown that Bcl-2 overexpression blocks Ca 2ϩ entry into or release from ER in response to many apoptotic stimuli. For example, overexpression of Bcl-2 decreases the ER Ca 2ϩ load (34, 35) and prevents or delays the depletion of Ca 2ϩ from ER after cells have received a treatment with apoptosis inducers such as thapsigargin, 2,5-di-(tert-butyl)-1,4-benzohydroquinone, cyclopiazonic acid, or ceramide (36 -38) .
The involvement of Ca 2ϩ signaling in apoptosis has been suggested by a number of recent studies (39, 40) . With transient increases in cytosolic Ca 2ϩ , many intracellular enzymes including phospholipases, proteases, and endonucleases can be activated, while prolonged or unregulated cytosolic Ca 2ϩ elevation can further lead to apoptosis or cell death (41, 42) . Although the molecular mechanism underlying apoptosis mediated by Ca 2ϩ in vivo remains to be fully defined, accumulation of mitochondrial Ca 2ϩ or activation of caspase-12 or other Ca 2ϩ -dependent intracellular enzymes may be the possible mechanisms (39, 43) . ER and mitochondria are two crucial organelles in the regulation of intracellular Ca 2ϩ homeostasis in cells. They are physiologically connected (44, 45) . After certain stimulations, rapid Ca 2ϩ accumulation in mitochondria always occurs immediately after ER Ca 2ϩ release (46, 47) . Such a rapid influx of Ca 2ϩ into mitochondria causes mitochondrial PTP to open and subsequent mitochondrial membrane permeability, mitochondrial metabolic alteration, reactive oxygen species (ROS) generation, and cytochrome c release. ROS is another potent promoter of cytochrome c release. In addition to regulating the cytochrome c-mediated caspase-dependent apoptosis, both Ca 2ϩ and ROS are important mediators of caspaseindependent apoptosis or necrosis (39, 43) .
Apoptosis, or programmed cell death, is a very important phenomenon in cytotoxicity induced by anticancer treatment. However, chemoresistance occurs when antiapoptotic protein Bcl-2 is overexpressed (48, 49) . Therefore, directly targeting Bcl-2 might overcome such chemoresistance. Based on the evidence that the heterodimerization of Bcl-2 and proapoptotic proteins is mediated by the BH3 domain of the proapoptotic proteins, we recently discovered a novel organic molecule, ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1) (C 17 H 17 BrN 2 O 5 ,), that binds to the proapoptotic protein BH3 domain binding sites on the surface pocket of Bcl-2 (8). HA14-1 is a synthetic cell-permeable small molecule with a molecular weight of 409. It specifically competes with Bak BH3 domain-derived peptide in binding Bcl-2 with an IC 50 of 9 M (8). HA14-1 alone or in combination with other anticancer agents has been shown to induce apoptosis effectively in many types of cancer cells including Ara-C-resistant HL-60 cells (8, 50 -52) . Cytochrome c release, caspase-9/-3 activation, and DNA fragmentation are evident in HA14-1-induced apoptosis. However, the molecular mechanism upstream of cytochrome c release upon HA14-1 treatment remains unclear. In this study, we investigated and identified several upstream signals in both ER and mitochondria that are critical for cytochrome c release in response to HA14-1.
EXPERIMENTAL PROCEDURES
Reagents-HA14-1 was synthesized and purified by our laboratory following our previously published method (53) . The detailed description of the routes of syntheses and structure has been published previously (8) . HA14-1 was prepared freshly by dissolving HA14-1 in Me 2 SO. It was diluted to appropriate concentrations in culture media before use in each experiment. EGTA acetoxymethyl ester, 5,5Ј,6,6Ј-tetrachloro-1,1Ј,3,3Ј-tetraethylbenzimidazolcarbocyanine iodide (JC-1), Calcium Green, and H 2 DCFDA (Molecular Probes) were dissolved in Me 2 SO, and aliquots were stored at Ϫ20°C. RU-360 (Calbiochem), carbonyl cyanide 3-chlorophenylhydrazone (CCCP), and vitamin E (Sigma) were dissolved in ethanol, and aliquots were stored at Ϫ20°C.
Cell Culture-The HL-60/Bcl-2 and HL-60/neo cell lines were obtained from Dr. Kapil N. Bhalla (University of Miami School of Medicine, Miami, FL). Each cell line (HL-60/Bcl-2 or HL-60/neo) had been stably transfected with either pZip-Bcl-2 or pZip-neo (control), respectively. The Bax Ϫ/Ϫ /Bak Ϫ/Ϫ knock-out and wild type MEF cell lines were obtained from Dr. Stanley J. Korsmeyer (Dana-Farber Cancer Institute, Boston, MA). All cells were cultured in RPMI medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 800 g/ml Geneticin (G418, Invitrogen). The concentrations of HA14-1 and other agents used and the treatment intervals are indicated in the following "Experimental Procedures" and under "Results." Cells were maintained in a humidified 5% CO 2 atmosphere at 37°C.
Measurement of Cell Viability-To measure the cytotoxic effects of HA14-1 on cell survival, cells were plated at 1 ϫ 10 5 cells/well in 96-well plates. Cells were treated with either a vehicle control or various concentrations of HA14-1 or HA14-1 plus other agents as indicated under "Results." At the end of each treatment, cell viability was measured by using a CellTiter 96® AQ ueous assay kit (Promega). This kit contains MTS-tetrazolium in which viable cells convert MTS-tetrazolium into a formazan colored product with an A of 490 nm. According to the manufacturer's instructions, 20 l of MTS-tetrazolium solution were added to 100 l of culture media and incubated for 3-4 h at 37°C. Afterward the absorbance at 490 nm was measured using a Wallac Victor 2 multilabel counter (PerkinElmer Life Sciences). Assays were performed in triplicate for each experiment; mean cell viability was compared with vehicle-treated controls. Each experimental data point was generated from at least three independent experiments.
Measurement of Caspase Activity-A CaspGLOW green caspase staining kit (Biovision) was used to measure the caspase-9 activity according to the manufacturer's instructions. Briefly cells (10 6 /ml), after different treatments, were incubated with fluorescein isothiocyanate-conjugated caspase-9 inhibitor LEHD-fmk, which specifically interacts with activated caspase-9. After incubation for 30 min at 37°C, the fluorescence intensity was determined using the Wallac Victor 2 multilabel counter. Increase in the fluorescence intensity was determined by comparing the level of the treated cells to that of vehicle controls.
Poly(ADP-ribose) Polymerase (PARP) Cleavage and DNA Fragmentation Assay-After appropriate treatments, cells were harvested by centrifugation, washed with ice-cold phosphate-buffered saline, and placed in 1) lysis buffer containing 0.02 M Tris, 1% Triton X-100, 0.14 M NaCl, 2 mM EDTA, 10 mol/ml protease inhibitor (Sigma), 1 mM phenylmethylsulfonyl fluoride, and dithiothreitol for PARP cleavage assay and 2) lysis buffer containing 50 mM Tris, pH 8.0, 10 mM EDTA, 0.5% SDS, 0.5% sodium chloride, and 100 g/ml proteinase K for 3 h at 56°C and for 1 h with 0.5 mg/ml RNase A at 37°C for DNA fragmentation assay. The PARP cleavage was determined on Western blot using rabbit polyclonal antibody (1:1,000) (Cell Signaling Technology). Signals were detected in the same way as that described for cytochrome c. For the DNA fragmentation assay, DNA was precipitated with isopropanol and analyzed by 2% agarose gel electrophoresis. After ethidium bromide staining, the presence of DNA in the gels was visualized under UV light.
Measurement of Cytochrome c Release-Mitochondrial versus cytosol fractions of cells were prepared using a mitochondrial/cytosol fractionation kit (Biovision). Cells at 1 ϫ 10 7 with or without different treatments were harvested by centrifugation at 700 ϫ g for 5 min and washed twice with cold phosphate-buffered saline. Afterward the cells were resuspended in a 250 l of extraction buffer containing protease inhibitor mixture and dithiothreitol (Biovision). After incubation on ice for 30 min, the cells were homogenized using a Kontes Dounce tissue grinder (Fisher) on ice. Homogenizations were centrifuged at 700 ϫ g for 10 min at 4°C, and the supernatant was collected. Then the collected supernatant was centrifuged again at 10,000 ϫ g for 30 min at 4°C. The resulting supernatants were harvested and designated as cytosolic fractions, and the pellets were resuspended in an appropriate buffer and designated as mitochondrial fractions. Protein content was determined using a Coomassie Blue assay (Bio-Rad). Similarly mitochondrial versus media fractions were obtained after treatments of purified mitochondria with HA14-1. For all experiments, fresh mitochondria were prepared and used within 4 h. The isolated mitochondria were incubated in a buffer containing 150 mM KCl, 3 mM KH 2 PO 4 , 5 mM succinate, 25 mM NaHCO 3 , 1 mM MgCl 2 , 2 M rotenone, 5 mM Tris-HCl, pH 7.4 and treated with 20 M HA14-1 alone, with 0.1 M Ca 2ϩ alone, or with HA14-1 plus 0.1 M Ca 2ϩ for 30 min at 37°C, respectively. Cytochrome c release in isolated mitochondria was monitored after treatment with HA14-1 in the presence or absence of CaCl 2 . The cytochrome c distributed in either fraction, the cytosol/media or the mitochondria, in each experiment was analyzed using Western blotting with anti-cytochrome c monoclonal antibody (1:1,000) (BD Pharmingen) or control antibody against ␤-actin (1:5,000) (Oncogene). Signals were detected using the horseradish peroxidase-conjugated anti-mouse secondary antibody (1:1,000) and enhanced chemiluminescence substrate kit (Amersham Biosciences).
Measurement of Intracellular Calcium Concentration-Cells at 1 ϫ 10 6 /ml were incubated with the calcium indicator dye Calcium Green at 5 M (Molecular Probes) for 30 min at 37°C in 5% CO 2 followed by a 10-min wash in phosphate-buffered saline. Previous studies have demonstrated that the vast majority of Calcium Green fluorescence is associated with ER as determined by using confocal microscopy with ER-Tracker-or MitoTracker-counterstained cells (54) . The fluorescence intensity of each indicator was measured using a FluoroMax-2 fluorescence spectrofluorometer (JoBin Yvon-Spex Instruments S.A., Inc.). Fluorescence was excited at 485 nm (F 485 ), and emitted fluorescence was recorded at 550 nm. To obtain the fluorescence maximum and minimum, cells were subsequently incubated with 0.1% Triton X-100 or 10 mM EGTA in the presence of saturating concentrations of extracellular Ca 2ϩ . Experiments were performed at 37°C with constant stirring. The Ca 2ϩ concentrations were calculated by the formula:
Determination of Changes in Mitochondrial Membrane Potential (⌬⌿ m )-Quantitative changes in ⌬⌿ m in cells at the early stage of apoptosis were measured using JC-1. This dye exists as a monomer with emission at 530 nm (green fluorescence) at low concentrations but forms J-aggregates with emission at 590 nm (red fluorescence) at high concentrations. Therefore, the fluorescence of JC-1 can be considered as an indicator of the relative mitochondrial membrane polarization state. Briefly cells were seeded at 1 ϫ 10 6 /ml. After different treatments, the cells were incubated with 10 M JC-1 at 37°C for 8 min, washed twice, and resuspended in phosphate-buffered saline. Relative fluorescence intensities were monitored using the FluoroMax-2 fluorescence spectrofluorometer with 490 nm excitation/535 nm emission and 570 nm excitation/610 nm emission. The ⌬⌿ m was expressed as the ratio of the fluorescence of J-aggregate (570 nm excitation/610 nm emission) to monomer (490 nm excitation/535 nm emission) forms of JC-1.
Confocal Microscopic Analysis of Bax Translocation-Cells (5 ϫ 10 5 ) were transfected with pEGFP-C3/Bax (obtained from Dr. Richard J. Youle, NINDS, National Institutes of Health, Bethesda, MD) using the cationic lipid LipofectAMINE TM 2000 (Invitrogen) according to the manufacturer's instruction. Each well contained 2 g of plasmid DNA and 8 g of LipofectAMINE 2000. After 3 h in a serum-free medium, an equal volume of culture medium was added. Twenty-four hours after transfection, the cells were washed once and cultured in regular media for an additional 24 h. Afterward cells were stained with MitoTracker Red at 20 ng/ml for 30 min, and then the cells were resuspended in fresh medium containing 20 M HA14-1 and transferred to a sealed mounting chamber. Images were collected using a confocal microscope (Olympus). The fluorescence excitation of GFP and MitoTracker Red were 488 and 568 nm, respectively.
Measurement of ROS Generation-The generation of ROS was measured in HL-60 cells at the end of different treatments according to the methods published by others (55) . Briefly, at the end of each treatment, the culture medium was removed and replaced with 100 l of fresh culture medium containing 100 M H 2 DCFDA, which was intracellularly de-esterified to dichlorodihydrofluorescein the substrate that ROS oxidizes to fluorescent dichlorofluorescein. After a 15-min incubation at 37°C, the fluorescence intensity was measured using the Wallac Victor 2 multilabel counter. Fluorescence was excited at 485 nm, and emitted fluorescence was recorded at 538 nm.
Statistical Analysis-The statistical analysis was performed using the Student's paired t test. Two-sided p values of Ͻ0.05 were considered statistically significant. Average values were expressed as mean Ϯ S.D.
RESULTS

Cell Death and Caspase Activation Induced by HA14-1 Can Be Prevented by Pretreatment with EGTA Acetoxymethyl Ester and Vitamin E
Cells were treated with various concentrations of HA14-1 plus either EGTA acetoxymethyl ester or vitamin E for different times as indicated (Fig. 1) . At the end of each treatment, cell viability was measured by using a CellTiter 96 AQ ueous assay kit (Promega). This kit contains MTS-tetrazolium in which viable cells convert MTS-tetrazolium into a formazan colored product with an A of 490 nm. Both HL-60/neo and HL-60/Bcl-2 cells were highly sensitive to HA14-1-induced cell death. About 30 -90% of HL-60/bcl-2 and 60 -90% of HL-60/neo cells lost their viability after a 3-h treatment with 20 -40 M HA14-1. However, a 1-h-long pretreatment with 25 M EGTA acetoxymethyl ester (Molecular Probes) or 200 g/ml vitamin E (Sigma) followed by a 3-h treatment with HA14-1 resulted in significantly reduced cell death as compared with the nonpretreatment control (Fig. 1A) . Caspases-9 activation (Fig. 1B) , PARP (Fig. 1C) , and subsequent DNA fragmentation (Fig. 1D) were also inhibited. 
HA14-1-caused Cytochrome c Release from Mitochondria Is Dependent on the Presence of Extramitochondrial Ca 2ϩ
The activation of the caspase cascade is believed to be dependent on the release of cytochrome c from mitochondria. To determine the amount of cytochrome c released from the mitochondria of the intact cells or purified mitochondria, cytosol and membrane fractions were prepared using a mitochondrial/ cytosol fractionation kit (Biovision). In intact cells, HA14-1 was able to induce cytochrome c release in a dose-and time-dependent manner. Around 30 min after treatment with 20 M HA14-1, cytochrome c in the cytosol fraction was detected. The maximum amount was reached 60 min after the treatment (Fig. 2) . There was no detectable cytochrome c present in the cytosol fraction of the vehicle-treated control. In cells pre-exposed to the EGTA acetoxymethyl ester for 1 h followed by HA14-1, cytochrome c release was severely blocked, suggesting that the Ca 2ϩ signal plays an important role in HA4-1-induced cytochrome c release. However, the same amount of HA14-1 did not elicit any detectable cytochrome c release from the isolated mitochondria at the same point in time in the absence of exogenous Ca 2ϩ . Cytochrome c release from the isolated mitochondria was elicited in the presence of HA14-1 plus 0.1 M Ca 2ϩ but not in the presence of the 0.1 M Ca 2ϩ alone. These data suggest that pre-existing signals in extramitochondria are activated and required for cytochrome c release under HA14-1 treatment. They also seem to indicate the sensitizing effect of HA14-1 on mitochondria. (Fig. 3) were detected in both HL-60/neo (Fig. 3A) and HL-60/Bcl-2 ( Fig. 3B ) cells seconds after receiving 20 M HA14-1, while no appreciable signals were observed in cells after receiving the Me 2 SO vehicle control. The amplitude of Ca 2ϩ spikes in HL-60/neo cells was 2 times higher than those in HL-60/Bcl-2 cells even when higher concentrations (Ͼ50 M) of HA14-1 were applied, suggesting that the ER Ca 2ϩ content in HL-60/Bcl-2 cells was significantly lower than that in HL-60/neo cells. In addition, after pretreatment with 25 M EGTA acetoxymethyl ester (Fig.   3D ), but not with 200 mg/ml vitamin E (Fig. 3C) , the amplitude of Ca 2ϩ spikes in response to HA14-1 was greatly diminished. This diminished Ca 2ϩ signal was positively correlated with inhibited cytochrome c release, caspase activation, and DNA fragmentation as indicated in Fig. 1 suggesting that the Ca 2ϩ signal may play a critical role in initiation of cytochrome c release and subsequent apoptosis in response to HA14-1.
HA14-1 Mediated
⌬⌿ m -Since Bcl-2 is expressed on the membranes of both ER and mitochondria, which are physiologically closely connected, HA14-1 may exert either a direct effect on mitochondrial Bcl-2, an indirect effect through ER Ca 2ϩ , or both to alter the ⌬⌿ m transition. We monitored the changes in ⌬⌿ m with time in response to HA14-1. The ⌬⌿ m transition was determined by a JC-1 assay, which was based on the potential-dependent accumulation of red fluorescent aggregates in mitochondria. The ⌬⌿ m transition was expressed as the ratio of fluorescence of J-aggregate (570 nm excitation/595 nm emission) and monomer (490 nm excitation/535 nm emission) forms of JC-1. As shown in Fig. 4 , changes in ⌬⌿ m were displayed within seconds to minutes after the HA14-1 treatment. At concentrations of HA14-1 higher than 20 M, the ⌬⌿ m transition occurred as early as seconds after the treatment and was similar to that of Ca 2ϩ spiking. When cells were pre-exposed to 25 M EGTA acetoxymethyl ester, 5 M RU-360 (an inhibitor of mitochondrial Ca 2ϩ uniporter), or 1 M CCCP (a mitochondrial uncoupler) the HA14-1-caused ⌬⌿ m transition was effectively inhibited.
Bax Translocation-Usually Bax translocation is closely associated with ⌬⌿ m transition. It can either be the cause, the result, or both. We further examined whether Bax translocation is elicited in situ in intact cells upon HA14-1 stimulation (Fig. 5) . The intracellular distribution of the Bax protein before and after treatment was evaluated by transfecting HL-60 cells with a GFP-Bax fusion protein construct, pEGFP-C3/Bax (obtained from Dr. Richard J. Youle, NINDS, National Institutes of Health). After a 15-min treatment with 20 M HA14-1, a significant change in the distribution of Bax from a diffuse to a punctate pattern was observed (Fig. 5A ). There was a nearly complete overlap between GFP-Bax fluorescence and the MitoTracker red fluorescence, which indicates the location of mitochondria (Fig. 5B) . On the other hand, the vehicle (Fig. 5C )-, EGTA acetoxymethyl ester (Fig. 5D )-, and RU-360 (Fig. 5E )-treated cells typically displayed a cytosolic diffuse pattern of fluorescence. Moreover the HA14-1-induced Bax translocation was not prevented by vitamin E pretreatment (Fig. 5F) .
The requirement for Bax in HA14-1-mediated cytochrome c release and cell death was further confirmed in Bax knock-out cells (Fig. 6) . The wild type Bax Ϫ/Ϫ or Bax Ϫ/Ϫ /Bak Ϫ/Ϫ MEF cells were incubated with various concentrations of HA14-1 for 4 h. After treatment, Bax Ϫ/Ϫ and Bax Ϫ/Ϫ /Bak Ϫ/Ϫ MEF cells showed more resistance to HA14-1-induced cell death than the wild type MEF cells (Fig. 6A) . Similarly, at 60 min after treatment with 20 M HA14-1, the released cytochrome c in the Bax Ϫ/Ϫ and Bax Ϫ/Ϫ /Bak Ϫ/Ϫ MEF cells was severely diminished (Fig. 6B) .
Generation of ROS-The fact that HA14-1-induced cytochrome c release as well as apoptosis was prevented by pretreatment with antioxidant vitamin E suggests that oxidative stress may be generated following HA14-1 treatment. As a means of determining the degree of overall oxidative stress, oxygen free radicals were monitored. Oxidation of H 2 DCFDA leads to increase in the fluorescent product dichlorofluorescein and permits quantification of relative levels of ROS. We examined the time course of ROS generation (Fig. 7) and analyzed its correlation with cytochrome c release. At the end of each treatment, cells were incubated with 10 M H 2 DCFDA, which was intracellularly de-esterified to dichlorohydrofluorescein, the substrate that ROS can oxidize to generate a fluorescent product of dichlorofluorescein. The elevation of ROS levels in cells in response to HA14-1 was dose-and time-dependent (Fig.  7A) . At 30 min after treatment with 20 M HA14-1, the ROS level had already started to increase, and it remained elevated for 60 min. The antioxidant vitamin E pretreatment attenuated the ROS generation (data not shown) as well as diminishing cytochrome c release, DNA fragmentation, and cell death as indicated in Figs. 1 and 2 , suggesting that ROS production was attributable to an apoptotic response to HA14-1. Comparison over time of the occurrence of ROS generation and cytochrome c release suggested that ROS generation is either the cause or the result of cytochrome c release. The dose-and time-dependent characteristics of ROS production together with ER Ca 2ϩ depletion (data not shown) induced by HA14-1 may contribute to caspase-independent apoptosis or cell death. This may explain why a pancaspase inhibitor, Z-VAD-fmk (Promega) at 10 M, was insufficient to block the HA14-1-induced cell death completely especially when higher concentrations (Ͼ30 M) of HA14-1 were applied (Fig. 7B) .
DISCUSSION
Cytochrome c release is a crucial step in apoptosis induced by many death stimuli that is controlled by Bcl-2 together with other members of the Bcl-2 family. Overexpression of Bcl-2 blocks, whereas overexpression of Bax or other proapoptotic proteins promotes, the release of cytochrome c. The precise molecular mechanism by which Bcl-2 prevents cytochrome c release in response to death stimuli is not fully understood. HA14-1 is a recently identified anticancer agent that targets the proapoptotic protein BH3 domain binding site on Bcl-2 and potently induces apoptosis in many types of cancer cells, especially the Ara-C-resistant HL-60/Bcl-2 cells, when used alone or in combination with other anticancer agents (8, 50, 51, 56) . In agreement with previous studies by others and us, we confirmed that HA14-1 alone at 20 M induced an apparent cytochrome c release, caspase-9/-3 activation, DNA fragmentation, and cell death (Fig. 1) . However, we found that the same amount of HA14-1, which induced an obvious cytochrome c release from the mitochondria of intact cells (Fig. 2A, lanes  1-3) , was insufficient to elicit the cytochrome c release from isolated mitochondria in the absence of exogenous Ca 2ϩ (Fig.   FIG. 3 . 2C, lane 1), suggesting that extramitochondrial signals such as Ca 2ϩ may play an essential role in HA14-1-induced cytochrome c release. The importance of intracellular Ca 2ϩ in HA14-1-induced apoptosis was supported by evidence that cytochrome c release, caspase-9 activation, and DNA fragmentation induced by HA14-1 were significantly reduced or blocked by the pretreatment with an intracellular Ca 2ϩ chelator, EGTA acetoxymethyl ester ( Fig. 1 and Fig. 2B, lane 2) .
ER is the major reservoir of intracellular Ca 2ϩ . It can release Ca 2ϩ in response to different apoptotic stimuli. Many lines of evidence have indicated that Bcl-2, as well as other proapoptotic proteins of the Bcl-2 family expressed on the ER membrane, plays a crucial role in controlling the release of ER Ca 2ϩ . It is highly possible that release of ER Ca 2ϩ occurs upon Bcl-2 targeting. This is confirmed by our observations that a Ca 2ϩ spike appeared within seconds after treatment with 20 M HA14-1 (Fig. 3) . The occurrence of the Ca 2ϩ spike was much earlier than cytochrome c release, which becomes detectable around 30 min (Fig. 2A, lane 1) and reached a maximum at 60 min (Fig. 2A, lane 2) after administration of the HA14-1. In fact, HA14-1 not only excited the early Ca 2ϩ spikes but also induced a sustained elevation of cytosolic Ca 2ϩ (Fig. 3) and a complete depletion of the late ER Ca 2ϩ store (data not shown). Whether the ER Ca 2ϩ release is caused by a direct effect of HA14-1 on ER Bcl-2 or an indirect effect via other intermediate mediators needs to be further investigated. ER Ca 2ϩ release has been indicated in apoptosis induced by many anticancer agents. Redistribution of the released ER Ca 2ϩ and activation of intracellular enzymes are two possible mechanisms of Ca 2ϩ -mediated apoptosis. It is known that ER and mitochondria are physiologically connected. Usually the released Ca 2ϩ from the ER is rapidly taken up by mitochondria (44, 45) . If a massive amount of Ca 2ϩ accumulates in mitochondria, it may cause irreversible PTP opening or ⌬⌿ m transition followed by a change in mitochondrial membrane permeability (57), cytochrome c release, ROS generation (58) , and induction of apoptosis and/or necrosis (59) . In addition to the mitochondria, the released ER Ca 2ϩ is redistributed into nuclei where it activates a number of Ca 2ϩ -dependent enzymes including endonuclease. The above described notion is supported by our finding that the blockade of the Ca 2ϩ spikes by pretreatment with an intracellular Ca 2ϩ chelator, EGTA acetoxymethyl ester, can prevent the subsequent cascade of apoptotic reactions induced by HA14-1.
Change in ⌬⌿ m is a common phenomenon accompanying cytochrome c release. It can either be the cause or the result of cytochrome c release. By using a ⌬⌿ m -sensitive fluorochrome, JC-1, we found that an early change in ⌬⌿ m transition was elicited by HA14-1 (Fig. 4) . The time required for the occurrence of such a ⌬⌿ m transition is comparable to that required for the occurrence of a Ca 2ϩ spike. Pretreatment with EGTA acetoxymethyl ester or RU-360 (an inhibitor of mitochondrial Ca 2ϩ uniporter) resulted in significant abolition of the HA14-1-induced early ⌬⌿ m transition. However, CCCP (a mitochon- drial Ca 2ϩ uncoupler) pretreatment had a less inhibitory effect. These data suggest that Ca 2ϩ entry into the mitochondria is critical for the activation of ⌬⌿ m transition. However, there is a need to determine whether HA14-1 exerts any sensitizing effect on mitochondria corresponding to the endogenous Ca 2ϩ -mediated change in ⌬⌿ m transition, which is similar to the sensitizing effect HA14-1 has on the exogenous Ca 2ϩ -mediated cytochrome c release from isolated mitochondria (Fig. 2C, lane  3) . We hypothesize that the transient uptake of Ca 2ϩ into mitochondria is sufficient to induce change in ⌬⌿ m transition in the HA14-1-sensitized mitochondria. Determining the conditions required to trigger the ⌬⌿ m transition in response to HA14-1 in isolated mitochondria might provide further useful information. Moreover it is extremely important to investigate whether the occurrence of change in ⌬⌿ m transition in response to HA14-1 is associated with any small amount of early cytochrome c release. Of course, such a small amount of cytochrome c may be difficult to detect.
Cytochrome c release is usually controlled by an amplificatory mechanism in the apoptotic cascade (12) . The amount of released cytochrome c must be sufficient to elicit an effective apoptotic cascade while overcoming the inhibitory effect of other factors, such as inhibitor of apoptosis (IAP) family members, on caspase activation. Although the inhibitors of IAPs, such as Smac/DIABLO, may be released accompanying or following the release of cytochrome c (60), IAPs are usually elevated in most types of cancer cells (61, 62) . Bax alone or together with the BH3-only proteins may play a critical role in mediating a sufficient amount of cytochrome c release because Bax can form channels, which allow direct cytochrome c release (26) . However, the channel forming activity of Bax can be neutralized by the presence of functional Bcl-2 (15) (16) (17) . By using Bax knock-out cells, we confirmed that Bax/Bak are critical for cytochrome c release and cell death induced by HA14-1 (Fig. 6) . In intact cells, an obvious Bax translocation occurred much earlier than the detectable cytochrome c release upon HA14-1 stimulation. Such Bax translocation can be inhibited by pretreatment with EGTA acetoxymethyl ester but not by vitamin E. This difference argues for distinct effects of Ca 2ϩ and ROS in mediating Bax translocation in this HA14-1-induced apoptosis system. It seems that ROS-mediated cytochrome c release does not require the translocation of Bax to mitochondria. The effects of early occurring Ca 2ϩ and ⌬⌿ m together with other unidentified apoptotic cytosols or PTP signals upon HA14-1 stimulation may be crucial in triggering Bax activation. It has been demonstrated extensively that translocation of Bax from cytosol to mitochondria facilitates the release of the cytochrome c. Despite many studies, the molecular mechanism of Bax action in vivo is still obscure. Bax may either interact with PTP complex or oligomerize itself to open or form a channel on the mitochondrial membrane (63) . Examination of cytochrome c release from isolated mitochondria in the presence or absence of HA14-1 and/or Bax will allow one to assess whether the neutralizing effect of Bcl-2 can be blocked and the channel forming activity of Bax can be enhanced by the presence of HA14-1.
Consistent with previous reports (8), our results showed that, after treatment with 10 -20 M HA14-1, caspase-9/-3 activation and DNA fragmentation were evident. However, when a higher concentration of HA14-1 (Ͼ30 M) was applied, a pancaspase inhibitor, Z-VAD-fmk, was insufficient to inhibit HA14-1-induced cell death completely (Fig. 7B ). This suggests that both caspase-dependent and -independent pathways may coexist in HA14-1-induced cell death. One of the important reasons for this may be that a large amount of Ca 2ϩ or ROS is generated before and/or after the cytochrome c release, resulting in a subsequent derangement of signaling and mitochondrial functions as well as the destruction of cellular components by Ca 2ϩ -activated catabolic enzymes and free radicals. This may explain why EGTA acetoxymethyl ester and vitamin E pretreatments exert a more protective effect than Z-VADfmk does against HA14-1-induced cell death (Fig. 1A) . In addition to Ca 2ϩ and ROS, release of other mitochondrial content, such as apoptosis-inducing factor, may also participate in the caspase-independent apoptosis induced by HA14-1 (64) .
Changes in Ca 2ϩ homeostasis in conjunction with ROS production have been indicated in apoptosis or necrosis induced by many anticancer agents (65, 66) . Ca 2ϩ and ROS exert an amplificatory feedback effect on each other. Sustained elevation of cytosolic Ca 2ϩ (Fig. 3) and ROS (Fig. 7A ) in response to HA14-1 was observed in our experiments. After challenge with a higher concentration of HA14-1, a large amount of Ca 2ϩ and ROS was generated within a short time. The pattern of ER Ca 2ϩ store depletion in HL-60 cells in response to HA14-1 was similar to that of other types of cells after treatment with different apoptotic inducers such as thapsigargin or cyclopiazonic acid (37, 67) . It is believed that, under normal physiological conditions, raising the Ca 2ϩ in the cytoplasm causes the activation, rather than inactivation, of mitochondrial metabolism when the accumulated Ca 2ϩ in the mitochondria is below a critical level. cytochrome c release or increase in cytosolic, mitochondrial, or nuclear Ca 2ϩ can activate many intracellular Ca 2ϩ -depepndent enzymes that are involved in both caspase-dependent and -independent cell death pathways (39) . Moreover the generation of a large amount of ROS can directly induce oxidative damage to lipids, proteins, and DNA (68) .
In conclusion, our results have demonstrated that signals generated by both ER and mitochondria upon HA14-1 treatment are essential for cytochrome c release and subsequent apoptosis. The special requirements of exogenous or endogenous Ca 2ϩ for cytochrome c release from isolated mitochondria or the mitochondria of intact cells suggest that Ca 2ϩ is an important signal upstream of cytochrome c release in response to HA14-1. Although the precise molecular mechanism responsible for the activation of ⌬⌿ m , Bax translocation, and ROS generation upstream of cytochrome c release in response to HA14-1 remains to be investigated, mitochondrial Ca 2ϩ accumulation and mitochondrial Bcl-2 presensitization play critical roles directly or indirectly in the initiation of these signals. Moreover, in addition to caspase-dependent apoptosis, the sustained elevation of cytosolic Ca 2ϩ and ROS may elicit caspaseindependent cell death. The involvement of both ER and mitochondrial signals suggests the importance of both organelles in HA14-1-induced apoptosis. The critical upstream signals of cytochrome c release found in this study have important implication for further understanding the molecular mechanism of Bcl-2-targeting agents and for developing new therapeutic strategies for cancer treatment.
